Table 3.
Univariable subset survival analysis results examining varying fractionation schemes and the correlating overall survival when all patients were divided by performance status strata in both the combined non-small cell lung cancer/small cell lung cancer (NSCLC/SCLC) patient cohort and the NSCLC patient-only cohort
| Fractionation scheme 8 + 10 Gy/1 fraction | Fractionation scheme 20 Gy/5 fractions | Fractionation scheme 30 Gy/10 fractions | |
|---|---|---|---|
| Good performance status (0–1) | Median overall survival 67 days | Median overall survival 112 days | Median overall survival 193 days |
| Combined NSCLC and SCLC cohorts | (n = 19, 95% confidence interval 58–108) | (n = 77, 95% confidence interval 95–158) | (n = 284, 95% confidence interval 170–213) |
| Mid performance status (2) | Median overall survival 71.5 days | Median overall survival 88 days | Median overall survival 152 days |
| Combined NSCLC and SCLC cohorts | (n = 32, 95% confidence interval 57–131) | (n = 107, 95% confidence interval 78–109) | (n = 186, 95% confidence interval 131–187) |
| Poor performance status (3–4) | Median overall survival 72 days | Median overall survival 80 days | Median overall survival 149 days |
| Combined NSCLC and SCLC cohorts | (n = 56, 95% confidence interval 40–90) | (n = 83, 95% confidence interval 66–107) | (n = 81, 95% confidence interval 115–185) |
| Good performance status (0–1) | Median overall survival 67 days | Median overall survival 106 days | Median overall survival 185 days |
| NSCLC cohort only | (n = 17, 95% confidence interval 58–129) | (n = 57, 95% confidence interval 92–137) | (n = 189, 95% confidence interval 162–207) |
| Mid performance status (2) | Median overall survival 67 days | Median overall survival 84 days | Median overall survival 139 days |
| NSCLC cohort only | (n = 29, 95% confidence interval 55–131) | (n = 88, 95% confidence interval 67–102) | (n = 130, 95% confidence interval 118–187) |
| Poor performance status (3–4) | Median overall survival 64 days | Median overall survival 75 days | Median overall survival 139 days |
| NSCLC cohort only | (n = 42, 95% confidence interval 38–103) | (n = 58, 95% confidence interval 56–108) | (n = 54, 95% confidence interval 100–185) |